McKesson Corporation (MCK) - Q3 2026 Summary
Business Context and Reporting Period
This summary covers the quarterly period ended December 31, 2025 (Fiscal Q3 2026). McKesson Corporation is a diversified healthcare services leader. Commencing in Q2 2026, the Company adopted a new segment reporting structure consisting of four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. Norwegian operations are classified as "Other" and were sold on January 30, 2026.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $106,158 | $95,294 | $307,135 | $268,228 |
| Gross Profit | $3,685 | $3,284 | $10,506 | $9,684 |
| Operating Income | $1,619 | $1,224 | $4,062 | $2,831 |
| Net Income (Attributable to MCK) | $1,186 | $879 | $3,080 | $2,035 |
| Diluted EPS | $9.59 | $6.95 | $24.73 | $15.80 |
| Operating Cash Flow (9M) | $2,734 (2025) vs. $(1,663) (2024) | |||
| Total Debt | $6,557 (Dec 31, 2025) | |||
| Cash & Equivalents | $2,959 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 11% in Q3 and 15% for the nine months ended Dec 31, 2025, driven by market growth in North American Pharmaceutical and significant expansion in Oncology & Multispecialty.
- Profitability: Net income attributable to McKesson increased 35% in Q3 and 51% for the nine-month period. Diluted EPS rose 38% and 57% respectively.
- Acquisitions: The Company completed two major acquisitions: PRISM Vision ($875M) in April 2025 and Core Ventures ($2.5B) in June 2025, both contributing to the Oncology & Multispecialty segment.
- Divestitures: The Company sold its Canadian retail businesses (Rexall/Well.ca) in late 2024 and completed the sale of its Norway operations in January 2026.
- Restructuring: Restructuring charges were $36M in Q3 2025 and $146M for the nine months, compared to $32M and $213M in the prior year periods. The Company anticipates total charges of $650M-$700M for enterprise-wide initiatives.
Guidance, Outlook, and Risks
- Capital Allocation: The Company returned $2.4B to shareholders in the first nine months via $2.1B in share repurchases and $280M in dividends. The quarterly dividend was raised to $0.82 per share. Approximately $5.4B remains authorized for share repurchases.
- Debt Management: In May 2025, the Company issued $2.0B in long-term notes (2030, 2032, and 2035 maturities) to fund the Core Ventures acquisition. The Company remains in compliance with all debt covenants.
- Legal Contingencies: Significant exposure remains regarding opioid-related litigation. As of Dec 31, 2025, total litigation liabilities were $5.7B. The Company has settled with 48 states and various other entities but faces ongoing claims from non-participating subdivisions and private plaintiffs.
- Segment Strategy: The Medical-Surgical Solutions segment is intended to be separated into an independent company (announced May 2025).
Investor Verification Checklist
- Opioid Litigation Reserves: Verify the adequacy of the $5.7B litigation liability reserve given ongoing appeals and non-settled claims (e.g., Baltimore, Philadelphia).
- Acquisition Integration: Assess the financial performance and integration progress of the Core Ventures and PRISM Vision acquisitions within the Oncology segment.
- Working Capital Trends: Monitor the impact of inventory build-up and accounts payable timing on operating cash flows, which showed significant volatility year-over-year.
- Medical-Surgical Spin-off: Track the timeline and financial implications of the planned separation of the Medical-Surgical Solutions segment.
- LIFO Adjustments: Review the impact of LIFO credits/charges on Cost of Sales, which fluctuated significantly ($10M credit in Q3 2025 vs. $89M charge in Q3 2024).